e-learning
resources
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil
Cinara Silva Feliciano, Lucas José Bazzo Menon, Livia Maria Pala Anselmo, Anzaan Dippenaar, Robin Mark Warren, Wilson Araújo Silva, Valdes Roberto Bollela
Source:
ERJ Open Res, 5 (3) 00043-2019; 10.1183/23120541.00043-2019
Journal Issue:
July
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Cinara Silva Feliciano, Lucas José Bazzo Menon, Livia Maria Pala Anselmo, Anzaan Dippenaar, Robin Mark Warren, Wilson Araújo Silva, Valdes Roberto Bollela. Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil. ERJ Open Res, 5 (3) 00043-2019; 10.1183/23120541.00043-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Rapid diagnosis of tuberculosis and rifampin resistance by GeneXpert MTB/RIF test
Source: International Congress 2018 – Diagnosis of tuberculosis
Year: 2018
Evaluation of Xpert MTB/RIF assay performance in diagnosing extrapulmonary tuberculosis among adults in a tertiary care centre in India
Source: Eur Respir J 2014; 44: 1090-1093
Year: 2014
Xpert MTB/RIF assay for rapid detection of Mycobacterium tuberculosis and rifampicin resistance
Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis
Year: 2012
How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
Source: Eur Respir J 2015; 45: 549-554
Year: 2015
MDR-TB treatment efficacy according of conventional method and Xpert MTB/RIF results in Republic of Moldova.
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis
Source: Eur Respir J 2013; 42: 708-720
Year: 2013
Comparative study of gene Xpert MTB/RIF, smear microscopy and TB MGIT culture in diagnosis of tuberculosis in India
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Role of GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampacin(R) resistance in patients in high risk DRTB
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 2
Year: 2014
Is Xpert MTB/Rif Ultra superior to Xpert MTB/Rif for the diagnosis of tuberculosis in children in Uzbekistan
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Year: 2021
A comparison between the efficiency of the Xpert MTB/RIF assay and nested PCR in identifying
mycobacterium tuberculosis
during routine clinical practice
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 2
Year: 2014
Tuberculosis diagnosis in rural Namibia using gene Xpert MTB/RIF testing
Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR
Year: 2016
Utility of Xpert® MTB/RIF assay for extrapulmonary tuberculosis, a two year study
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?
Source: Eur Respir J 2012; 40: 161-168
Year: 2012
Early tuberculosis treatment monitoring by Xpert® MTB/RIF
Source: Eur Respir J 2012; 39: 1269-1271
Year: 2012
MDR-TB treatment efficacy by results of Xpert MTB/RIF assayin the Stavropol region of the Russian Federation
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Comparison of genotype MTBDRplus assay for rapid detection of rifampicin and isoniazid resistance with conventional drug susceptibility tests in a tertiary care hospital in India
Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR
Year: 2016
Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting
Source: Eur Respir J, 51 (3) 1702345; 10.1183/13993003.02345-2017
Year: 2018
Cost–benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals
Source: Eur Respir J 2016; 47: 575-587
Year: 2016
Influence of early diagnostics with Xpert MTB/RIF on MDR TB patients treatment efficacy
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe
Source: Eur Respir J, 51 (5) 1800346; 10.1183/13993003.00346-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept